Plymouth, Mi., USA - October 28, 2014, Plymouth, Mi., USA - ProNAi Therapeutics Inc., a biotechnology company, announced that it has added five seasoned executives to its senior management team.
Article continues below
Angie You, Chief Business & Strategy Officer and Head of Commercial
Dr. You heads the newly created position of Chief Business & Strategy Officer & Head of Commercial, and will lead the Company's strategic and transactional business and commercial efforts.
Prior to joining ProNAi, Dr. You served as the Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, HR and business development. During her tenure, she helped in two successful rounds of financing and led the business development process resulting in the acquisition of Aragon Pharmaceuticals by Johnson & Johnson.
Prior to Aragon, Dr. You served as Chief Business Officer at a number of companies including Synosia Therapeutics and Ren Pharmaceuticals. She also worked at Venrock Ventures, focused on new company formation, and ran the BD process for Anacor Pharmaceuticals, a Venrock portfolio company, resulting in an early Phase 2a licensing agreement with Schering Plough providing an initial $50M upfront and up to $575 million in milestones.
After completing her undergraduate degree in Chemistry at Harvard College, and a Ph.D. in Biochemistry from Harvard University, Dr. You started her biotech career at McKinsey Consulting, focusing mainly on strategy, marketing and innovation-focused projects with biotech clients.
Ms. Chapman heads the newly created position of Senior Vice President, Clinical Operations, with corporate accountability for the overall operational deployment of clinical studies.
Prior to joining ProNAi, Ms. Chapman was the Portfolio Director at PAREXEL International where she was the senior point of contact for all issues related to the financial and operational execution of Phase II-IV global clinical trials for one of PAREXEL's largest Strategic Alliance Partners.
Previously, Ms. Chapman was the Vice President of Clinical Operations at YM Biosciences Inc. She has more than 25 years of experience in clinical drug development at several pharmaceutical and contract research organizations in Canada and the U.S., including Viventia Biotech, AAI Pharma, Bayer Inc., AstraZeneca and MDS.
Chandra Lovejoy, Senior Vice President, Global Regulatory Affairs and Head of Quality
Ms. Lovejoy heads the newly created position of Senior Vice President, Global Regulatory Affairs and Head of Quality, with more than 15 years of progressive experience in global regulatory affairs and drug development in large and small companies overseeing pre-clinical through post-marketing phases.
Most recently, Ms. Lovejoy was the Vice President of Global Regulatory Affairs at Endocyte, and prior to that she held a leadership role in Regulatory Affairs at Genentech, primarily on the Avastin program.
Emma McCann, Vice President, Program Management
Ms. McCann heads the newly created position of Vice President, Program Management and joins ProNAi with more than 14 years of progressive experience in clinical research and program management.
Ms. McCann was formerly Sr. Director, Program Management at YM BioSciences Inc. She holds a B.Sc. (Hons) in Bio-Medical Science from The University of Guelph, Ontario.
James Smith, Vice President, Corporate Affairs
Mr. Smith heads the newly created position of Vice President, Corporate Affairs, primarily responsible for the Company's strategic investor relations and corporate communications activities.
Mr. Smith was formerly Vice President, Corporate Development at SQI Diagnostics. Prior to this, he was Vice President, Corporate Affairs at YM BioSciences Inc., a public drug development company acquired by Gilead Sciences Inc.
Prior to YM, Mr. Smith led the Healthcare practice at TMX Equicom, a strategic investor relations consulting firm acquired by the Toronto Stock Exchange. He gained his initial capital markets experience as a biotechnology analyst at a venture capital firm. He also conducted research for eight years primarily focused on animal cell culture. ■